BioMarin Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US09061G1013

SecurityBMRN / BioMarin Pharmaceutical Inc.
InstitutionTIFF INVESTMENT PROGRAM - TIFF Multi-Asset Fund
Latest Disclosed Ownership15,084 shares
Latest Disclosed Value $ 829,167
TIFF INVESTMENT PROGRAM - TIFF Multi-Asset Fund reports 649.91% decrease in ownership of BMRN / BioMarin Pharmaceutical Inc.

On August 27, 2025 - TIFF INVESTMENT PROGRAM - TIFF Multi-Asset Fund filed a NPORT-P form disclosing ownership of 15,084 shares of BioMarin Pharmaceutical Inc. (US:BMRN) valued at $829,167 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing -2,743 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of -649.91% during the quarter. The current value of the position is $856,319 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP BioMarin Pharmaceutical EC US09061G1013 15,084 17,827 -649.91 829 -529.53 0.0589
2025-05-29 2025-03-31 NP BioMarin Pharmaceutical EC US09061G1013 -2,743 -10,490 -135.41 -194 -135.28 -0.0151
2025-05-29 2025-03-31 NP BioMarin Pharmaceutical EC US09061G1013 7,747 3,463 80.84 548 94.66 0.0428
2025-02-28 2024-12-31 NP BioMarin Pharmaceutical EC US09061G1013 4,284 3,288 330.12 282 192.71 0.0215
2024-02-27 2023-12-31 NP BioMarin Pharmaceutical EC US09061G1013 996 -1,265 -55.95 96 -52.00 0.0075
2023-11-27 2023-09-30 NP BioMarin Pharmaceutical EC US09061G1013 2,261 -618 -21.47 200 -19.68 0.0160
2023-08-28 2023-06-30 NP BioMarin Pharmaceutical EC US09061G1013 2,879 935 48.10 250 31.75 0.0195
2023-05-25 2023-03-31 NP BioMarin Pharmaceutical EC US09061G1013 1,944 23 1.20 189 -4.55 0.0144
2023-02-24 2022-12-31 NP BioMarin Pharmaceutical EC US09061G1013 1,921 -681 -26.17 199 -10.00 0.0157
2022-11-28 2022-09-30 NP BioMarin Pharmaceutical EC US09061G1013 2,602 234 9.88 221 12.24 0.0182
2022-08-23 2022-06-30 NP BioMarin Pharmaceutical EC US09061G1013 2,368 8 0.34 196 -4.85 0.0152
2021-02-05 2020-12-31 NP BioMarin Pharmaceutical EC US09061G1013 2,360 -534 -18.45 207 -6.36 0.0132
2020-11-25 2020-09-30 NP BioMarin Pharmaceutical EC US09061G1013 2,894 2,894 220 0.0152
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.